Stoke Therapeutics, Inc. (NASDAQ:STOK) Shares Sold by Skorpios Trust

Skorpios Trust lowered its position in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 17.9% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 8,906,181 shares of the company's stock after selling 1,937,500 shares during the period. Stoke Therapeutics accounts for 99.8% of Skorpios Trust's portfolio, making the stock its biggest holding. Skorpios Trust owned about 16.92% of Stoke Therapeutics worth $109,457,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of STOK. Nisa Investment Advisors LLC boosted its position in Stoke Therapeutics by 53.2% during the 2nd quarter. Nisa Investment Advisors LLC now owns 2,989 shares of the company's stock worth $40,000 after acquiring an additional 1,038 shares during the period. Price T Rowe Associates Inc. MD lifted its holdings in Stoke Therapeutics by 5.5% in the first quarter. Price T Rowe Associates Inc. MD now owns 31,431 shares of the company's stock worth $425,000 after purchasing an additional 1,642 shares during the period. The Manufacturers Life Insurance Company grew its position in Stoke Therapeutics by 16.7% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 13,964 shares of the company's stock valued at $189,000 after buying an additional 1,994 shares in the last quarter. Quest Partners LLC bought a new position in Stoke Therapeutics in the 2nd quarter valued at about $29,000. Finally, Los Angeles Capital Management LLC increased its stake in Stoke Therapeutics by 7.2% during the 2nd quarter. Los Angeles Capital Management LLC now owns 66,765 shares of the company's stock valued at $902,000 after buying an additional 4,508 shares during the period.

Analyst Upgrades and Downgrades

STOK has been the subject of several recent analyst reports. Needham & Company LLC reiterated a "buy" rating and issued a $22.00 price objective on shares of Stoke Therapeutics in a report on Thursday, August 8th. Wedbush reiterated an "outperform" rating and set a $17.00 price target on shares of Stoke Therapeutics in a research report on Thursday, July 11th. Leerink Partners initiated coverage on Stoke Therapeutics in a report on Monday, October 14th. They issued an "outperform" rating and a $18.00 price objective for the company. HC Wainwright reaffirmed a "buy" rating and set a $35.00 target price on shares of Stoke Therapeutics in a report on Wednesday, September 11th. Finally, Leerink Partnrs raised shares of Stoke Therapeutics to a "strong-buy" rating in a report on Friday, October 11th. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus price target of $20.83.

Insider Buying and Selling

In other news, major shareholder Skorpios Trust sold 1,937,500 shares of the stock in a transaction on Thursday, September 19th. The stock was sold at an average price of $14.05, for a total value of $27,221,875.00. Following the completion of the sale, the insider now owns 8,906,181 shares in the company, valued at $125,131,843.05. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 11.30% of the company's stock.

Stoke Therapeutics Stock Performance

Shares of NASDAQ:STOK traded down $0.14 during midday trading on Friday, reaching $11.91. The company had a trading volume of 238,514 shares, compared to its average volume of 776,231. The company has a fifty day simple moving average of $13.48 and a two-hundred day simple moving average of $13.68. The firm has a market cap of $620.76 million, a price-to-earnings ratio of -4.94 and a beta of 0.97. Stoke Therapeutics, Inc. has a 1-year low of $3.35 and a 1-year high of $17.58.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last announced its earnings results on Wednesday, August 7th. The company reported ($0.46) EPS for the quarter, topping the consensus estimate of ($0.57) by $0.11. Stoke Therapeutics had a negative net margin of 683.35% and a negative return on equity of 57.89%. The company had revenue of $4.83 million during the quarter, compared to analysts' expectations of $3.33 million. Analysts expect that Stoke Therapeutics, Inc. will post -2.1 EPS for the current year.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.